tbuckley/cabot-search huggingface dataset:
Nonmelanoma Skin Cancer in Nonwhite Organ Transplant Recipients
Authors: Ellen N. Pritchett, Alden Doyle, Christine M. Shaver, Brett Miller, Mark Abdelmalek, Carrie Ann Cusack, Gregory E. Malat, Christina Lee Chung
Journal: JAMA Dermatology (2016)

Organ transplant recipients have a higher incidence of skin cancer. This risk is magnified over time and with continued exposure to immunosuppression. Skin cancer in nonwhite patients is associated with greater morbidity and mortality owing to diagnosis at a more advanced stage, which suggests that nonwhite organ transplant recipients are at even higher risk.To describe demographic and clinical factors and the incidence of skin cancer in nonwhite organ transplant recipients.We performed a retrospective medical record review of patients who were organ transplant recipients (154 were white and 259 nonwhite [black, Asian, Hispanic, Pacific Islander]) seen from November 1, 2011, to April 18, 2016 at an academic referral center.Variables were analyzed and compared between racial groups, including sex, age, race/ethnicity, Fitzpatrick type, type and location of skin cancer, type of organ transplanted, time to diagnosis of skin cancer after transplantation, and history of condyloma acuminata and/or verruca vulgaris.Most of the 413 patients (62.7%) evaluated were nonwhite organ transplant recipients; 264 were men, and 149 were women. Their mean (SD) age was 60.09 (13.59) years. Nineteen skin cancers were identified in 15 patients (5.8%) representing 3 racial/ethnic groups: black (6 patients), Asian (5), and Hispanic (4). All squamous cell carcinomas in blacks were diagnosed in the in situ stage, located on sun-protected sites, and occurred in patients whose lesions tested positive for human papilloma virus (HPV) and/or who endorsed a history of condyloma acuminata or verruca vulgaris. Most skin cancers in Asians were located on sun-exposed areas and occurred in individuals who emigrated from equatorial locations.Nonwhite organ transplant recipients are at risk for developing skin cancer posttransplantation. Follow-up in a specialized transplant dermatology center and baseline total-body skin examination should be part of posttransplantation care in all organ transplant recipients, including nonwhite patients. A thorough inspection of the groin and genitalia is imperative in black organ transplant recipients. History of HPV infection, particularly in black organ transplant recipients, and sun exposure/emigration history in Asian organ transplant recipients should be documented. Vigilant photoprotection may be of lesser importance in the prevention of skin cancer in black organ transplant recipients. Risk factors for nonwhite organ transplant recipients differ between races/ethnicities and warrant further study in efforts to better counsel and prevent skin cancer in these patients.
Prevalence and characteristics of patients with stage IV solid tumors who receive no anticancer therapy.
Authors: Alexander C. Small, Che-Kai Tsao, Erin L. Moshier, Benjamin Adam Gartrell, Juan P. Wisnivesky, James H. Godbold, Cardinale B. Smith, Guru Sonpavde, William K. Oh, Matt D. Galsky
Journal: Journal of Clinical Oncology (2012)

6065 Background: Clinicians caring for patients with cancer are well aware that a subset of patients who present with metastatic solid tumors never receive anticancer therapy for reasons including poor functional status, comorbidities, and patient preference. The prevalence and characteristics of this population have not previously been described. Methods: The National Cancer Database was queried for patients diagnosed with metastatic (stage IV) solid tumors including breast, cervix, colon, kidney, small-cell and non-small cell lung [NSCLC and SCLC], prostate, rectum and uterus. Patients who received neither radiation therapy nor systemic therapy were identified. Other factors such as age, race, income, insurance status, and diagnosis year were assessed. In an exploratory analysis, log-binomial regression was used to estimate prevalence ratios (PR) for the proportion of untreated stage IV to treated stage IV cancer cases according to these factors. Results: From 2000-2008, 773,233 patients with stage IV cancer were identified of whom 159,284 (21%) received no anticancer therapy (Table). Patients with NSCLC accounted for 55% of untreated patients. Across all cancer types, older age (PR range 1.37-1.49, all p&lt;0.001), black race (PR range 1.05-1.32, all p&lt;0.001), lack of medical insurance (PR range 1.47-2.46, all p&lt;0.001), and lower income (except uterus) (PR range 0.91-0.98 for every $10,000 income, all p&lt;0.001) were associated with increased prevalence of not receiving treatment. Conclusions: Approximately 20% of patients who present with stage IV solid tumors never receive anticancer therapy. These findings have potential implications with regards to healthcare policy and access to care. [Table: see text]
Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample
Authors: Sylvia Taylor, Pio Lopez, Lily Weckx, Charissa Borja-Tabora, Rolando Ulloa-Gutierrez, Eduardo Lazcano-Ponce, Angkool Kerdpanich, Miguel Angel Rodriguez Weber, Abiel Mascareñas de Los Santos, Juan-Carlos Tinoco, Marco Aurelio P. Safadi, Fong Seng Lim, Marcela Hernandez-de Mezerville, Idis Faingezicht, Aurelio Cruz-Valdez, Yang Feng, Ping Li, Serge Durviaux, Gerco Haars, Sumita Roy-Ghanta, David W. Vaughn, Terry Nolan
Journal: Journal of Infection (2016)
Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Authors: Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Abid Mohiuddin, Michal Rose, Caroline Behler, Andrew Han, Yvonne Efebera, Antoun Houranieh, Mary T. Brophy, Abraham Zimelman, Rao H Prabhala, Hussain I. Saba, Catherine Klein, Paulette Mehta, Teresa Hayes, David Roodman, Alan K. Lichtenstein
Journal: Blood (2010)
Effectiveness of Daclatasvir Based Therapy in Patients with Chronic Hepatitis C in Europe: Experience from the Named Patient Program
Authors: N. Weis, J. Young, H. Hofer, W. Irving, O. Weiland, E. Giostra, J.M. Pascasio, L. Castells, M. Prieto, C. Lefevre, D. Evans, H. Bucher, J.L. Calleja
Journal: Journal of Hepatology (2016)
Salivary Cortisol Determination after Acth Stimulation Test for Diagnosis of Adrenal Insufficiency in Patients with Liver Cirrhosis
Authors: J. Profitós, L. Albert, O. Giménez-Palop, M. Vergara, B. Dalmau, M. Miquel, M. Casas, I. Capel, D. Subías, M. Rigla, E. Berlanga, J. Sánchez
Journal: Journal of Hepatology (2016)
Transjugular Intra Hepatic Porto Systemic Shunt Placement Induces Modifications of Cerebral Multimodal MRI in Cirrhotic Patients, even in the Absence of Development of Hepatic Encephalopathy
Authors: M. Rudler, N. Weiss, V. Perlarg, M. Mallet, S. Tripon, R. Valabregue, D. Galanaud, D. Thabut
Journal: Journal of Hepatology (2016)
Physical Activity, Air Pollution, and the Risk of Asthma and Chronic Obstructive Pulmonary Disease
Authors: Jack E. Fisher, Steffen Loft, Charlotte S. Ulrik, Ole Raaschou-Nielsen, Ole Hertel, Anne Tjønneland, Kim Overvad, Mark J. Nieuwenhuijsen, Zorana J. Andersen
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Rationale: Physical activity enhances uptake of air pollutants in the lung, possibly augmenting their harmful effects on chronic lung disease during exercise.Objectives: To examine whether benefits of physical activity with respect to the risk of asthma and chronic obstructive pulmonary disease (COPD) are moderated by exposure to high air pollution levels in an urban setting.Methods: A total of 53,113 subjects (50–65 yr) from the Danish Diet, Cancer, and Health cohort reported physical activity at recruitment (1993–1997) and were followed until 2013 in the National Patient Register for incident hospitalizations for asthma and COPD. Levels of nitrogen dioxide (NO2) were estimated at subject residences at the time of recruitment. We used Cox regression to associate physical activities and NO2 (high/medium/low) with asthma and COPD, and then introduced an interaction term between each physical activity and NO2.Measurements and Main Results: A total of 1,151 subjects were hospitalized for asthma and 3,225 for COPD during 16 years. We found inverse associations of participation in sports (hazard ratio [95% confidence interval]: 0.85 [0.75–0.96]) and cycling (0.85 [0.75–0.96]) with incident asthma, and of participation in sports (0.82 [0.77–0.89]), cycling (0.81 [0.76–0.87]), gardening (0.88 [0.81–0.94]), and walking (0.85 [0.75–0.95]) with incident COPD admissions. We found positive associations between NO2 and incident asthma (1.23 [1.04–1.47]) and COPD (1.15 [1.03–1.27]) hospitalizations (comparing ≥21.0 μg/m3 to <14.3 μg/m3). We found no interaction between associations of any physical activity and NO2 on incident asthma or COPD hospitalizations.Conclusions: Increased exposure to air pollution during exercise does not outweigh beneficial effects of physical activity on the risk of asthma and COPD.
High Rates of Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy: Community-Based Real World Outcomes
Authors: R. Wong, M. Nguyen, C. Chan, H. Trinh, A. Huynh, M. Ly, H. Nguyen, K. Nguyen, S. Torres, J. Yang, B. Liu, R. Garcia, T. Bhuket, B. Levitt, E. DaSilvera, R. Gish
Journal: Journal of Hepatology (2016)
Impact of Genetic Polymorphisms on Immune Response and Clinical Features in MDS.
Authors: Bianca Serio, Anna Jankowska, Giridharan Ramsingh, Zach Nearman, Hadrian Szpurka, Ramon Tiu, Christine O’Keefe, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2006)
Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).
Authors: P. Lara, J. Longmate, A. Argiris, B. J. Gitlitz, P. C. Mack, D. H. Lau, M. Koczywas, N. B. Leighl, D. R. Gandara
Journal: Journal of Clinical Oncology (2010)

7533 Background: The proteasome inhibitor PS-341 sensitizes tumor cells to chemoinduced apoptosis. In preclinical NSCLC models, p53-dependent growth arrest after PS-341 treatment resulted in an antagonistic interaction if PS-341 preceded Doc. The reverse sequence (Doc -> PS- 341) was optimal, associated with reduced protein levels of Bcl-2 and increased apoptosis with cleavage of caspase-3 and PARP. To further evaluate these observations, we conducted a randomized phase II trial of concurrent vs. sequential Doc-PS-341. Methods: Platinum-pretreated metastatic NSCLC patients (pts) were randomized to concurrent (Arm 1) or sequential (Arm 2) Doc 75 mg/m2 IV followed by PS-341, every 3 weeks. In Arm 1, PS-341 (1.6 mg/m2 IV) was given on days 1 and 8. In Arm 2, PS-341 was on days 2 and 8. Pts must have performance status (PS) 0-1 and adequate end-organ function. Prior erlotinib (n=13) and treated/controlled brain mets were allowed. Primary endpoint was RECIST response (RR); progression-free (PFS) and overall survival (OS) were secondary endpoints. With 40 pts per arm, there was 90% probability to correctly “pick the winner” if the RR on the two arms were 0.05 vs. 0.13, or 0.10 vs. 0.20, or 0.15 vs. 0.27. Results: 81 pts were randomized: 40 in Arm 1, 41 in Arm 2. Pt characteristics and efficacy by arm and overall are summarized below. Grade (Gr) 3+ toxicities were mostly due to myelosuppression (Arm 1 vs. 2): leukopenia (6 vs. 11), lymphopenia (10 vs. 2), neutropenia (8 vs. 15), and thrombocytopenia (0 vs. 3). One pt each had Gr 4 hyponatremia and syncope. One pt in Arm 2 died after experiencing Gr 4 heme toxicities, Gr 3 neuropathy and anorexia. Conclusions: The combination of Doc plus PS-341 concurrently given on day 1 has similar RR as sequential therapy, but results in OS exceeding prior published OS estimates for either agent alone or in combination. (NO1 CM-62209) Arm 1 (concurrent) Arm 2 (sequential) Overall Male sex 23 (57%) 20 (49%) 43 (53%) PS=0 17 (42%) 21 (51%) 38 (47%) Median age, years 61 62 61 Response rate (all partial) 4 (10%) 4 (10%) 8 (10%) Disease control rate (partial + stable) 20 (50%) 20 (49%) 40 (49%) PFS, 6 months (%) 30% 17% 25% OS, median in months (95% CI) 13.3 (7, 17) 7.8 (6, 18) 10.5 (7, 14) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Millennium Millennium
Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients
Authors: Antonio M Risitano, Michael Storek, Leonardo Sahelijo, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, Judith C.W. Marsh, Modupe Elebute, Casey L O'Connell, Austin G. Kulasekararaj, Giridharan Ramsingh, Serena Marotta, Andrzej Hellmann, Ante S. Lundberg
Journal: Blood (2015)
Sequence Analysis for Resistance Monitoring following a Single Dose of RG-101, an Anti-MIR Targeting Microrna-122, in Chronic Hepatitis C Patients
Authors: M.H. van der Ree, F. Stelma, J.M.L. de Vree, S.B. Willemse, M. van der Valk, Ad.C. van Nuenen, A. Patick, P. Grint, S. Neben, A. Pavlicek, E. van der Veer, N.A. Kootstra, H.W. Reesink
Journal: Journal of Hepatology (2016)
Cancer of the Nasopharynx: UICC Monograph Series, Vol. 1. A Symposium Organized by the International Union Against Cancer. C. S. Muir and K. Shanmugaratnam (eds.). Flushing, New York: Medical Examination Publishing Company, Inc., 1967. 259 pp.
Authors: Marvin A. Schneiderman
Journal: Cancer Research (1969)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Authors: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, Malcolm Mason, Chris Metcalfe, Peter Holding, Michael Davis, Tim J. Peters, Emma L. Turner, Richard M. Martin, Jon Oxley, Mary Robinson, John Staffurth, Eleanor Walsh, Prasad Bollina, James Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Alan Paul, Philip Powell, Stephen Prescott, Derek J. Rosario, Edward Rowe, David E. Neal
Journal: New England Journal of Medicine (2016)

The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Prevalence and Management of Drug-Drug Interactions (DDIs) with Ombitasvir (OBV), Paritaprevir/R (PRV/r) ± Dasabuvir (DBV) ± Ribavirin (RBV) in Pacients with Chronic Hepatitis C in Real-Life Clinical Practice
Authors: E. González-Colominas, M.-C. Londoño, R.M. Morillas, X. Torras, S. Mojal, S. Lens, D. López, A. Gallego, Z. Mariño, M. Ardèvol, N. Pagès, R. Solà, J.A. Carrión
Journal: Journal of Hepatology (2016)
Effect of New Cerebral Ischemic Lesions on the Delirium Occurrence After Transcatheter Aortic Valve Replacement
Authors: Masieh Abawi, Freek Nijhoff, Pierfrancesco Agostoni, Rehana de Vries, Arjen J.C. Slooter, Marielle H. Emmelot-Vonk, Michiel Voskuil, Tim Leiner, Pieter A. Doevendans, Pieter R. Stella
Journal: Journal of the American College of Cardiology (2016)
Risks of Liver Complications after a Long-Term Follow-Up in Patients with Chronic Hepatitis C with Sustained Virologic Response
Authors: B. Kutala, M.-P. Ripault, E. Estrabaud, F. Khelifa-Mouri, R. Nait, N. Boyer, N. Giuily, C. Castelnau, T. Asselah, P. Marcellin
Journal: Journal of Hepatology (2016)
Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin
Authors: Belen Rubio-Gonzalez, Jasmine Zain, Lino Garcia, Steven T. Rosen, Christiane Querfeld
Journal: JAMA Dermatology (2016)

an ongoing partial response (Figure, B).However, tumor biopsies were declined by the patient.Furthermore, the creatinine level remained stable at 5.25 mg/dL.Vismodegib treatment was tolerated without any clinically relevant adverse effects.Interestingly, the common adverse effects such as muscle cramps of the lower leg, fatigue, weight loss, or dysgeusia were not reported.Only alopecia developed within the first 4 weeks of treatment.The patient's quality of life was significantly improved by reepithelialization of ulcerated and bleeding areas of the tumor.In particular, the formation of an epiphysis of the right midface contributed to an improvement of the patient's quality of life.At last follow-up, treatment with vismodegib was being continued at the same dose.Discussion | To our knowledge, this is the first case report that describes vismodegib use and its tolerability in a patient with chronic stage 4 kidney disease receiving dialysis treatment.This case indicates good efficacy and tolerability of vismodegib in a patient with advanced BCC.Based on this patient's response and tolerability, we suggest that vismodegib may offer a safe treatment option to be considered in the setting of adequate medical monitoring for patients with renal insufficiency receiving dialysis therapy.However, further observations are needed to evaluate the safety profile of vismodegib in patients with renal impairment.
Black Gains in Life Expectancy
Authors: Victor R. Fuchs
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Natural Killer Cells Modulate Endothelial Progenitor Cells in Alcoholic Chronic Liver Disease Patients by Increasing Pro-Inflammatory Cytokines and Chemokines
Authors: P. Srivastava, R. Sehgal, S.S. Shastry, E. Huang, J. Gamble, S. Kaur, G. Ramakrishna, G. McCaughan, S.K. Sarin, N. Trehanpati, D. Seth
Journal: Journal of Hepatology (2016)
Progression of Non-Alcoholic Fatty Liver Disease Towards Steatohepatitis is Differentially Mediated by Inflammasome-Induced Downstream Pathways IL-1 and IL-18
Authors: S. Hohenester, C. Einer, R. Wimmer, J. Nagel, F.P. Reiter, S. Schulz, C. Rust, A.L. Gerbes, H. Zischka, G. Denk
Journal: Journal of Hepatology (2016)
Directed Differentiation of IPS Cells to Hepatic Stellate Cells
Authors: M. Coll, L. Perea, R. Boon, J. Vallverdú, D. Rodrigo-Torres, D. Blaya, M. Llopis, I. Graupera, B. Aguilar, C. Verfaillie, P. Ginès, P. Sancho-Bru
Journal: Journal of Hepatology (2016)
Urinary Metabolomic Analysis or Early Prediction of Sepsis in Acute-on -Chronic Liver Failure Patients
Authors: J.S. Maras, S. Das, Md.S. Hussain, A. Chaudhary, S.M. Shasthry, S. Sharma, C. Junot, R. Moreau, S.K. Sarin
Journal: Journal of Hepatology (2016)
PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057
Authors: Richard J. Gralla, David Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael Derosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
Journal: Journal of Thoracic Oncology (2016)
Diminished Replication and Viral Compartmentalization of Hepatitis C Virus in Hepatocellular Carcinoma Tissue
Authors: D. Harouaka, R.E. Engle, K. Wollenberg, G. Diaz, A. Tice, F. Zamboni, S. Govindarajan, H.J. Alter, D.E. Kleiner, P. Farci
Journal: Journal of Hepatology (2016)
Angiomatous extension of intestinal type carcinoma relates to microvessel density and VEGF-expression, when compared to diffuse type carcinoma in oesophageal, proximal and distal gastric cancer
Authors: A. Driessen, V. Winnepenninckx, Ludo Filez, Philippe Nafteux, Dirk Van Raemdonck, M. Peeters, Eric Van Cutsem, Karin Haustermans, Paul De Leyn, Antoon Lerut, Freddy Penninckx, Nadine Ectors
Journal: Gut (2001)
Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria
Authors: E. Andre, L. Goeminne, A. Cabibbe, P. Beckert, B. Kabamba Mukadi, V. Mathys, S. Gagneux, S. Niemann, J. Van Ingen, E. Cambau
Journal: Clinical Microbiology and Infection (2016)

The rpoB gene codes for the RNA polymerase β subunit, which is the target of rifampicin, an essential drug in the treatment of tuberculosis and other mycobacterial infections. This gene is present in all bacteria, but its length and nucleotide sequence vary between bacterial species, including mycobacteria. Mutations in the rpoB gene alter the structure of this protein and cause drug resistance. To describe the resistance-associated mutations, the scientific and medical communities have been using, since 1993, a numbering system based on the Escherichia coli sequence annotation. Using E. coli reference for describing mutations in mycobacteria leads to misunderstandings, particularly with the increasing use of whole genome sequencing, which brought an alternative numbering system based on the Mycobacterium tuberculosis rpoB sequence. We propose using a consensus numbering system for the reporting of resistance mutations based on the reference genomes from the species interrogated (such as strain H37Rv for M. tuberculosis). This manuscript provides the necessary figures and tables allowing researchers, microbiologists and clinicians to easily convert other annotation systems into one common language.
Patients transferred for primary PCI in APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial have only modest symptom onset to PCI delays and good outcomes
Authors: Petr Widimsky, W. Douglas Weaver, Frans Van de Werf, Franz-Josef Neumann, Diego Ardissino, Amanda Stebbins, Annoud van t'Hof, Torsten T Nielsen, Paul W Armstrong, Christopher B Granger
Journal: Journal of the American College of Cardiology (2007)
Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals
Authors: E. Degasperi, A. Aghemo, S. De Nicola, P. Bono, A. Orlandi, R. D’Ambrosio, R. Soffredini, R. Perbellini, G. Lunghi, M. Colombo
Journal: Journal of Hepatology (2016)